PatternsRadar
Sign in

BIOFILCHEMBiofil Chemicals & Pharmaceuticals Limited

NSE
29.37INR-0.89 (-2.94%)Close · 20 Nov 2026
14 Nov 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹48 CrMarket cap
92.7P/E (TTM)
64.0%Delivery

Filings & corporate actions

38 results filed
CSV
Next results · Q3 FY27
Expected 7 Feb 2027 – 15 Feb 2027
Estimate: filed 38–46 days after quarter end, last 5 times
2026
  • 14 NovresultsResults · Q2 FY27 · standalone-2.3%NSE
  • 9 OctshareholdingShareholding · 30 Sept 2026+2.1%NSE
  • 11 AugresultsResults · Q1 FY27 · standalone+0.1%NSE
  • 16 JulshareholdingShareholding · 30 Jun 2026-0.6%NSE
  • 30 MayresultsResults · Q4 FY26 · standalone-0.8%NSE
  • 8 AprshareholdingShareholding · 31 Mar 2026+2.5%NSE
  • 13 FebresultsResults · Q3 FY26 · standalone-4.3%NSE
  • 8 JanshareholdingShareholding · 31 Dec 2025-3.6%NSE

Reaction to results · all yearsrose on day 0 in 12 of 79 CSV

QuarterFiledDay 0+5D+20DRel vol
Q2 FY2714 Nov 2026-2.3%——4.0×
Q1 FY2711 Aug 2026+0.1%-5.3%-3.6%0.5×
Q4 FY2630 May 2026-0.8%+0.6%-0.4%2.0×
Q3 FY2613 Feb 2026-4.3%-5.4%-16.3%0.5×
Q2 FY2613 Nov 2025-0.3%-3.3%-14.5%0.3×
Q1 FY2612 Aug 2025-2.9%-0.4%+0.9%0.9×
Q4 FY2530 May 2025-1.5%+6.8%-4.2%0.9×
Q3 FY2511 Feb 2025+1.4%-3.3%-15.6%1.4×
Q2 FY2515 Nov 2024-3.9%-0.7%+4.5%0.8×
Q1 FY2513 Aug 2024-1.5%+6.8%+4.6%0.5×
Q4 FY2431 May 2024-1.0%+0.1%+7.2%3.5×
Q3 FY247 Feb 2024+5.0%0.0%-9.5%0.6×
Q2 FY2410 Nov 2023+0.2%0.0%+5.9%0.2×
Q1 FY2414 Aug 2023-0.5%-0.3%+4.3%1.3×
Q4 FY2331 May 2023-1.2%-2.5%-1.9%1.7×
Q3 FY2315 Feb 2023+1.8%-5.2%-12.0%0.5×
Q2 FY2315 Nov 2022-2.2%+3.9%+1.0%0.3×
Q1 FY2310 Aug 2022-0.3%-1.6%+1.1%0.7×
Q4 FY2231 May 2022-0.2%-1.9%-10.1%0.6×
Q3 FY2215 Feb 2022-0.7%-7.4%-5.3%0.5×
Q2 FY2213 Nov 2021-0.8%-3.5%+0.5%1.0×
Q1 FY2214 Aug 2021-1.5%-12.5%-6.2%0.2×
Q4 FY211 Jul 2021+0.5%+0.1%+6.1%0.5×
Q3 FY2113 Feb 2021-5.0%-0.7%+1.3%0.4×
Q2 FY2112 Nov 2020+5.0%+40.6%+139.1%0.9×
Q1 FY2126 Aug 2020-4.9%-26.1%+24.8%5.8×
Q4 FY201 Jul 2020+1.2%0.0%+100.4%1.6×
Q3 FY2015 Feb 2020-4.4%-21.1%-33.8%0.5×
Q2 FY2015 Nov 2019+4.6%+30.6%+162.0%1.4×
Q1 FY2014 Aug 2019-4.2%-5.9%-18.5%4.7×
Q4 FY1931 May 20190.0%+2.1%-22.9%0.9×
Q3 FY1926 Feb 2019+1.6%+5.5%+3.9%0.3×
Q2 FY1926 Nov 2018+0.7%-2.1%+5.6%1.6×
Q1 FY1931 Aug 2018+1.0%0.0%-20.1%1.3×
Q4 FY1823 Jun 20180.0%-14.0%-9.8%0.0×
Q3 FY1819 Mar 2018-1.4%+0.7%+6.2%0.2×
Q2 FY1821 Nov 2017-2.7%-1.6%-10.1%0.1×
Q1 FY1818 Aug 2017-4.9%-2.2%-13.9%—
Q4 FY1717 Jun 2017————
Q3 FY1717 Feb 2017————
Q2 FY1722 Nov 2016————
Q1 FY1713 Aug 2016————
Q4 FY161 Jun 2016————
Q3 FY1614 Feb 2016————
Q2 FY1613 Nov 2015————
Q1 FY1616 Aug 2015————
Q4 FY152 Jun 2015————
Q3 FY1520 Feb 2015————
Q2 FY1520 Nov 2014————
Q1 FY1520 Aug 2014————
Q4 FY1411 Jun 2014————
Q3 FY1415 Feb 2014————
Q2 FY1411 Dec 2013————
Q1 FY1423 Aug 2013————
Q4 FY132 Jul 2013————
Q3 FY1321 Feb 2013————
Q2 FY1319 Nov 2012————
Q1 FY1323 Aug 2012————
Q4 FY1230 May 2012————
Q3 FY1214 Feb 2012————
Q2 FY1217 Nov 2011————
Q1 FY1225 Aug 2011————
Q4 FY117 Jun 2011————
Q3 FY1115 Feb 2011————
Q2 FY1115 Nov 2010————
Q1 FY1116 Aug 2010————
Q4 FY104 Jun 2010————
Q3 FY1030 Jan 2010————
Q2 FY105 Nov 2009————
Q1 FY1031 Jul 2009————
Q4 FY0930 Jun 2009————
Q3 FY092 Feb 2009————
Q2 FY097 Nov 2008————
Q1 FY091 Aug 2008————
Q2 FY0811 Feb 2008————
Q3 FY086 Feb 2008————
Q1 FY089 Aug 2007————
Q4 FY0717 Jul 2007————
Q3 FY073 Feb 2007————
Average-0.8%-0.8%+6.8%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q2 FY27

Revenue YoY-87.7%
Profit YoY+37.9%
Interest cost YoY-55.4%
Revenue QoQ-86.5%
Profit QoQ+5.7%
CAGR2Y3Y4Y5Y6Y7Y
Revenue-15.0%-13.7%+5.4%-9.3%-7.0%-4.1%
Profit-1.9%-8.6%-2.2%+1.3%-16.5%-11.5%

Key data

Open29.51
Day range28.31 – 30.39
52-week range25.60 – 46.34
From 52w high-36.6%
RSI (14)44.0
ATR (14)1.62
Volume26.2K
Avg volume (20D)12.5K
Rel volume2.09×
Volatility (1Y)53.0%
Turnover₹7.7L
Traded value (NSE)₹7.7L
VWAP29.52
SMA 50 / 20030.79 / 32.66
Price band20%

Delivery percentage

Latest · 20 Nov 202664.0%
20-day avg68.6%
1-year avg64.1%
Percentile (own history)47th
Range15.0–100.0%
Sessions1,761

Over the last 20 sessions BIOFILCHEM settled 68.6% of its traded quantity, which is unusually high for an NSE equity. Its one-year average is 64.1%, so recent sessions are running 4.6 points higher than usual. The latest session ranks higher than 47% of the 1,761 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

Dividends, deals & holders

Dividend yield0.00%
Dividend, trailing 12M₹0.00
Paid every year for0 yr
Shareholders24.7K · -1.4% QoQ
Net bulk deals, 30D0.00%
Block deals, 30D₹0
Last bulk buy85 days ago

Performance returns

1D1W1M3M6M1Y
Price-2.94%-6.44%+1.14%-4.58%-6.91%-25.13%

Valuation

Market cap₹48 Cr
Market cap (NSE)₹48 Cr
Free-float cap₹25 Cr
P/E (TTM)92.7
P/E (NSE)95.5
EPS (TTM)0.32
P/B2.2
Net margin (TTM)2.3%
Other income / PBT44.0%
ROE2.4%
Debt / equity0.10
Shares outstanding1.63Cr
Listed12 Jun 1996

Ownership

Promoter46.79%
Promoter Δ QoQ0.00 pp
Public53.21%
FII0.00%
DII0.08%
Pledged0.00%

Quarterly results · standalone

Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue (₹ Cr)0.97.612.41.7
YoY chg-94.0%-9.4%+92.0%-87.7%
Net profit (₹ Cr)0.10.20.10.1
YoY chg-51.9%+6.3%-95.5%+37.9%
Net margin9.2%2.8%0.9%6.9%
EPS0.050.130.070.07

Shareholding over time

By quarter

30 Sept 2026 · promoter 46.79% · public 53.21%
30 Jun 2021: promoter 46.82%30 Sept 2021: promoter 46.82%31 Dec 2021: promoter 46.82%31 Mar 2022: promoter 46.82%30 Jun 2022: promoter 46.82%30 Sept 2022: promoter 46.82%31 Dec 2022: promoter 46.82%31 Mar 2023: promoter 46.82%30 Jun 2023: promoter 46.82%30 Sept 2023: promoter 46.82%31 Dec 2023: promoter 46.82%31 Mar 2024: promoter 46.82%30 Jun 2024: promoter 46.82%30 Sept 2024: promoter 46.82%31 Dec 2024: promoter 46.82%31 Mar 2025: promoter 46.82%30 Jun 2025: promoter 46.82%30 Sept 2025: promoter 46.79%31 Dec 2025: promoter 46.79%31 Mar 2026: promoter 46.79%30 Jun 2026: promoter 46.79%30 Sept 2026: promoter 46.79%
2021-062026-09
  • Promoter
  • Public and others
Promoter
46.79%
Public
53.21%
Promoter change
0.00 pp
Filed
9 Oct 2026
FII
0.00%
DII
0.08%
Promoter pledged
0.00%

Who the public is

Mutual funds
0.00%

0.00 pp QoQ

Insurance
0.00%

0.00 pp QoQ

FPI
0.00%

0.00 pp QoQ

Retail ≤ ₹2L
34.74%

-0.23 pp QoQ

HNI > ₹2L
3.81%

+0.15 pp QoQ

NRI
1.41%

+0.09 pp QoQ

Bodies corporate
11.60%

-0.11 pp QoQ

Shareholders
24,660

-1.4% QoQ

Major holders

As of 30 Sept 2026
HolderTypeHolding
SCOPE FINANCE COMPANY PRIVATE LIMITEDPromoter · Corporate13.90%
MID (INDIA) PHARMACEUTICALS PVT LTDPromoter · Corporate7.22%
STARLINE EQUIFIN PRIVATE LIMITEDCorporate7.07%
CYANO FINANCE AND SALES PVT. LTD.Promoter · Corporate5.39%
MEENA SHAHPromoter · Individual4.06%
NIYATI SHAHPromoter · Individual4.05%
KETAN SHAHPromoter · Individual3.03%
SANDEEP SHAHPromoter · Individual2.60%
ROMIL SHAHPromoter · Individual2.35%
KSL AND INDUSTRIES LIMITEDCorporate1.89%

Every promoter-group member, and each public holder above 1%, as filed.

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.

Price-band hits

Loading…

Sessions the stock closed at the limit of its daily price band, from NSE's end-of-day list. A stock pinned at the band could not trade past it that day.

Insider trades

Insiders net, 30d
₹0
Insiders net, 90d
₹0
Promoters net, 90d
₹0
Insider buyers, 90d
0
Last promoter buy
none on record
Disclosures on record
9
0 open-market of the newest 9
By year

No open-market insider trades among the recent disclosures.

SEBI insider-trading disclosures, equity only. Dated by the day NSE broadcast them; the trade itself is often weeks earlier. The figures count promoters, directors and KMPs buying or selling on the exchange — not ESOPs, gifts, transfers within the promoter group or pledges. Stake is the holding after, as filed; the change beneath it scales that by the share counts before and after. Regulation is the PIT clause cited, and “told” the day the insider informed the company.

How the insider figures are countedPromoters buying in the open market, market-wideEvery stock on this session

Bulk & block deals · 27 Aug 2026

CSV
12 of 104 deals
By year
DateDealClientQuantityPriceValue
27 Aug 2026Sell · bulkORION STOCKS LTD89.8K32.93₹29.6L
27 Aug 2026Buy · bulkORION STOCKS LTD3.9K32.94₹1.3L
26 Aug 2026Sell · bulkORION STOCKS LTD2.11L32.63₹68.8L
26 Aug 2026Buy · bulkIRAGE BROKING SERVICES LLP1.53L32.76₹50.1L
26 Aug 2026Buy · bulkORION STOCKS LTD61.8K32.46₹20.1L
26 Aug 2026Sell · bulkIRAGE BROKING SERVICES LLP19.5K32.64₹6.4L
25 Aug 2026Sell · bulkORION STOCKS LTD2.83L33.00₹93.6L
25 Aug 2026Buy · bulkIRAGE BROKING SERVICES LLP2.47L32.97₹81.5L
25 Aug 2026Buy · bulkORION STOCKS LTD59.1K32.69₹19.3L
25 Aug 2026Sell · bulkIRAGE BROKING SERVICES LLP45.4K32.88₹14.9L
24 Aug 2026Sell · bulkORION STOCKS LTD2.50L32.29₹80.9L
24 Aug 2026Buy · bulkIRAGE BROKING SERVICES LLP1.99L32.15₹63.9L

A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.

Every stock on this session →

Takeover-code disclosures

Loading…

Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.

Every stock on this session →

Short selling, lending & margin

Loading…

Shares bought on broker margin funding (MTF) and still held at the day’s end, and the amount brokers have lent against them.

Exchange surveillance

20 Nov 2026
  • Under 100 traders in 30 days · since 12 Oct 2026 — Fewer than 100 distinct investors traded it in the last 30 days.
  • P/E > 50 (4 quarters) · since 12 Aug 2026 — P/E above 50 on the last four quarters’ earnings.

Price band: 20% · not in the F&O ban.

From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes.

Every stock on this session →

Financials · quarterly statement

Standalone
₹ crore, as filed
By year
 Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27Q2 FY27
Revenue from operations5.015.28.42.414.28.46.413.50.97.612.41.7
Other income0.00.40.00.00.00.22.80.10.10.10.10.1
Total income5.115.68.52.414.28.69.313.60.97.712.41.8
Total expenses4.915.38.22.414.08.36.513.50.87.212.31.6
└ Finance costs0.00.00.00.00.00.00.00.00.00.00.00.0
└ Depreciation0.10.10.10.10.10.10.10.10.10.10.10.1
Profit before tax0.10.30.20.00.20.32.80.10.10.50.10.2
Tax expense0.00.00.10.00.10.10.40.00.00.30.00.0
Net profit0.10.20.20.00.20.22.40.10.10.20.10.1
EPS0.060.150.100.010.100.121.480.050.050.130.070.07
Net margin1.85%1.64%2.01%1.01%1.16%2.39%37.48%0.62%9.25%2.80%0.88%6.91%
PBT margin2.25%1.81%2.70%1.36%1.56%3.04%42.95%0.82%12.46%6.20%1.09%9.23%
Tax rate17.65%9.50%25.75%25.61%25.77%21.36%12.72%25.16%25.77%54.74%18.64%25.18%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 14 Nov 2026.

Balance sheet & cash flow · half-yearly

Standalone
₹ crore, as filed
By year

Balance sheet

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Total assets31.442.247.142.051.055.442.853.3
Current assets22.433.438.433.642.648.435.946.4
└ Cash & equivalents0.00.00.10.20.10.20.10.0
└ Other bank balances0.00.02.20.10.10.13.32.0
└ Current investments0.00.00.00.00.00.00.00.0
└ Trade receivables20.527.433.025.538.340.827.638.5
└ Inventories1.25.12.56.83.33.54.04.9
Total equity17.317.718.218.418.821.321.621.8
└ Attributable to owners17.317.718.218.418.821.321.621.8
└ Share capital16.316.316.316.316.316.316.316.3
Borrowings0.50.60.40.50.50.03.02.2
└ Current0.50.60.40.50.50.03.02.2
└ Non-current0.00.00.00.00.00.00.00.0
Trade payables12.623.327.622.731.033.317.128.7
Current liabilities13.724.228.523.331.833.720.730.9
Total liabilities14.124.528.923.632.234.121.331.5
Net debt0.50.5(1.8)0.20.2(0.3)(0.3)0.2
Debt / equity0.030.030.020.020.030.000.140.10
Current ratio1.631.381.351.441.341.441.731.50

Cash flow, year to date

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Operating cash flow(0.1)(0.0)2.4(2.1)(1.9)(3.6)(0.6)(0.4)
└ Capex(0.0)0.0(0.0)0.0(0.1)(0.1)(0.2)(0.1)
Free cash flow(0.1)(0.0)2.4(2.1)(2.0)(3.6)(0.8)(0.5)
Investing cash flow(0.0)0.0(0.0)0.0(0.1)4.11.1(0.0)
Financing cash flow0.00.0(0.1)(0.0)(0.0)(0.5)2.5(0.9)
└ Dividends paid0.00.00.00.00.00.00.00.0
└ Buybacks0.00.00.00.00.00.00.00.0
Net change in cash(0.1)0.02.2(2.1)(2.0)0.13.1(1.3)

From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.

Announcements & board meetings

Loading…

As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.

Every stock on this session →

BIOFILCHEM at a glance

  • BIOFILCHEM closed at ₹29.37 on 20 Nov 2026, -2.94% on the day, -25.1% over one year, 36.6% below its 52-week high of ₹46.34.
  • Delivery was 64.0% of traded quantity on 20 Nov 2026, the 47th percentile of its own 1,761 sessions with a reading (20-session average 68.6%, 1-year average 64.1%).
  • Market capitalisation is ₹48 crore at a trailing P/E of 92.7 (trailing EPS ₹0.32).
  • Q2 FY27 results (standalone, filed 14 Nov 2026): revenue ₹2 crore (-87.7% year on year), net profit ₹0 crore (+37.9%); the price moved -2.3% on the first session after.
  • Promoters held 46.79% at 30 Sept 2026, unchanged on the previous filing.
  • Q3 FY27 results are expected between 7 Feb 2027 and 15 Feb 2027, going by past filing dates — an estimate, not an announcement.

About

Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE829A01014
SeriesEQ
Listed12 Jun 1996
NSE market cap · 17 Nov 2026₹51 Cr
Free-float market cap (NSE)₹27 Cr
Shares outstanding (NSE)1.63Cr
History from27 Jul 2017
Sessions2,292

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.